Despite the challenges of understanding how and when to perform pharmacogenomics tests when prescribing neuropsychiatric drugs, its clinical use is increasing. Similarly, so are the options for obtaining pharmacogenomic tests. In 2004, the FDA approved the first pharmacogenomic testing platform—the Roche AmpliChip CYP450 Genotyping Test (Roche Molecular Systems Inc. and Affymetrix Inc., Pleasanton, CA), for CYP2D6 and CYP2C19—which facilitated the availability of genetic testing at multiple clinical centers.46 Since then, several companies have introduced testing panels to the market and have offered them to physicians or directly to potential customers. These innovations changed the arena of genetic testing and revealed the need for development and implementation of support systems such as pharmacogenomic education to clinicians, guideline development, and performance of large, randomized clinical trials.
